Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Bone problems news

Show

From To
People with HIV/HCV co-infection at increased risk of kidney disease and bone disorders

Hepatitis C virus (HCV) infection in people with HIV co-infection is associated with an increased risk of liver disease and liver-related death and also several important non-liver related

Published
02 January 2017
By
Michael Carter
Co-morbidities are common and rising among people with HIV in the US

People living with HIV are increasingly experiencing a range of non-AIDS-related co-morbidities as the population ages, including cardiovascular disease, kidney impairment and bone loss leading to fractures,

Published
19 December 2016
By
Liz Highleyman
Tenofovir alafenamide works well and improves kidney and bone markers in older people living with HIV

A co-formulation of tenofovir alafenamide (TAF) plus emtricitabine, used with a third antiretroviral drug, maintained viral suppression as well as tenofovir disoproxil fumarate (TDF) plus emtricitabine in older

Published
10 November 2016
By
Liz Highleyman
Less than 100% adherence to HIV therapy, even with viral suppression, can lead to more inflammation and immune activation

Research involving men taking antiretroviral therapy, all with an undetectable viral load, has shown that imperfect adherence to therapy is associated with higher levels of key markers of

Published
12 October 2016
By
Michael Carter
Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey?

I’ve heard more than a few patients ask, what should I do? If I’m already taking Complera, Stribild or Truvada, should I switch to the newer drug formulation with tenofovir alafenamide (TAF)?

Published
20 September 2016
From
BETA blog
Bone loss and recovery in MSM aged 13-24 using PrEP for a year

Results from an open-label study in young people using PrEP showed that impact on bone health might be important is daily dosing is used for many years.

Published
19 September 2016
From
HIV i-Base
Bone loss partially recovers after stopping PrEP, twice-yearly kidney monitoring is enough for most

Young adults taking Truvada for pre-exposure prophylaxis (PrEP) experienced a modest decrease in bone mineral density early on, but this stabilised after a year and those who stopped

Published
26 July 2016
By
Liz Highleyman
Switching from tenofovir DF to TAF improves bone and kidney safety

People with HIV who switched from the older tenofovir disoproxil fumarate (TDF) formulation to tenofovir alafenamide (TAF) were more likely to maintain viral load suppression and showed improvements

Published
11 July 2016
By
Liz Highleyman
Not So Fast: Do people with HIV really experience accelerated aging?

Recent talk about HIV and aging has almost always been scary. A number of studies conclude that people living with HIV have so-called “accelerated aging”—meaning they will suffer heart attacks, strokes, cancers, and osteoporosis more often and sooner than those without HIV. Well, this is one article on aging and HIV that will challenge the concept of people living with HIV having an early expiration date. Instead, we can look at what we know and what we don’t, to get a better idea of what the risks are for HIV-positive people growing older—and what they can do about them.

Published
08 July 2016
From
Positively Aware
Fearing Drugs’ Rare Side Effects, Millions Take Their Chances With Osteoporosis

Millions of Americans are missing out on a chance to avoid debilitating fractures from weakened bones, researchers say, because they are terrified of exceedingly rare side effects from drugs that can help them.

Published
02 June 2016
From
New York Times
← First12345...11Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.